NewsHome - A-Z Cancer Glossary

BI @ ASCO 2013
Lung Cancer: Not Just One Disease
New Phase III data for afatinib* and nintedanib...

BI @ ASCO 2013 <br/>Lung Cancer: Not Just One Disease

BI @ ASCO 2013
BI to present highly anticipated new Phase III results

BI @ ASCO 2013 <br/>BI to present highly anticipated new Phase III results

BI @ ASCO 2013
New Phase III data for afatinib* and nintedanib*

BI @ ASCO 2013<br/>New Phase III data for afatinib* and nintedanib*

US FDA Grants Priority Review to Boehringer Ingelheim's Afatinib

Unprecedented progression-free survival benefit with afatinib

Boehringer Ingelheim submits first compound
BI submits first oncology compound, afatinib* f...

Boehringer Ingelheim submits first compound

Lung Cancer Animated Infographic

EGFR Mutation Backgrounder

Afatinib Backgrounder

LUX-Lung 3 Fact Sheet

Afatinib delivers unprecedented first line efficacy

LUX-Lung 3 Results - Prof James Yang
Interview with Prof James-Chih-Hsin Yang Direc...

LUX-Lung 3 Results - Prof James Yang

LUX-Lung 7 Clinical Trial Infographic

LUX-Lung 8 Clinical Trial Infographic

Pivotal study on afatinib
Pivotal study on afatinib may challenge standar...

Pivotal study on afatinib

Cancer statistics and incidence rates

Importance of EGFR Mutation Testing
Interview with Dr Vera Hirsh Associate Profess...

Importance of EGFR Mutation Testing

Lung Cancer Backgrounder

LUX-Lung 3 Results - Prof Thomas Lynch
Interview with Prof Thomas J. Lynch, MD Direct...

LUX-Lung 3 Results - Prof Thomas Lynch

LUX-Lung 3 Trial Design
Interview with Prof Tony Shu Kam Mok, MD Depar...

LUX-Lung 3 Trial Design

LUX-Lung 6 and other Afatinib Trials
Interview with Prof James-Chih-Hsin Yang Direc...

LUX-Lung 6 and other Afatinib Trials

LUX-Lung 7 & 8 Trials
Interview with Prof Thomas J. Lynch, MD Direct...

LUX-Lung 7 & 8 Trials

Nintedanib Backgrounder

Targeted Cancer Therapies Backgrounder

Pivotal Phase III Results
Media Alert: Pivotal Phase III Results for Afat...

Pivotal Phase III Results

Afatinib
Interview with Prof Thomas J. Lynch, MD Direct...

Afatinib

Biomarkers
Interview with Prof Thomas J. Lynch, MD Direct...

Biomarkers

Angiokinase Inhibition and Nintedanib (BIBF 1120) Infographic

BIBF 1120* in mCRC
BIBF 1120* in patients with metastatic colorect...

BIBF 1120* in mCRC

ErbB family Blockade and Afatinib Infographic

LUME Lung 2 clinical trial infographic

LUME-Lung 1 infographic

Lung cancer incidence statics in Europe Infographic

LUX Lung 1 clinical trial fact sheet

LUX Lung 1 Clinical Trial Infographic

LUX Lung 2 clinical cancer trial

LUX Lung 2 Clinical Trial Infographic

LUX-Lung 3 Clinical Trial Layered Infographic

The Changing Face of Cancer Infographic

New Lux-Lung 1 data December 2010
New subgroup analysis of the LUX-Lung 1 trial s...

New Lux-Lung 1 data December 2010

Angiokinase inhibitors in lung cancer
Interview with Marianne Nicolson, MD, FRCP Con...

Angiokinase inhibitors in lung cancer

Better lung cancer treatment

Improving outcomes in lung cancer

Personalising cancer care and the future of cancer treatments
Interview with John Heymach, MD, PhD Associate...

Personalising cancer care and the future of cancer treatments

Non small cell lung cancer overview
Interview with David Ross Camidge, MD, PhD As...

Non small cell lung cancer overview

Afatinib lung cancer trial results
Afatinib (BIBW 2992*) triples progression free ...

Afatinib lung cancer trial results

EGFR Mode of Action

Boehringer Ingelheim and DxS sign agreement
Boehringer Ingelheim and DxS sign an agreement ...

Boehringer Ingelheim and DxS sign agreement

Boehringer Ingelheim to commence Lux Lung 3 study
Boehringer Ingelheim and DxS sign agreement for...

Boehringer Ingelheim to commence Lux Lung 3 study

Boehringer Ingelheim to present new data at ASCO 2009
Boehringer Ingelheim to Present New Phase II Cl...

Boehringer Ingelheim to present new data at ASCO 2009

Press release LUME-Lung 1+2 November 2008
First pivotal trials begin for Boehringer Ingel...

Press release LUME-Lung 1+2 November 2008

Clinical trials data BIBF 1120*
Data suggests promising overall survival and pr...

Clinical trials data BIBF 1120*

Lux phase 3 BIBW 2992 (afatinib)
New data on BIBW 2992*, a potent, irreversible,...

Lux phase 3 BIBW 2992 (afatinib)

Ovarian cancer backgrounder

AGO-OVAR 12/LUME-Ovar 1 Ovarian Cancer Trial Infographic

State of Research in Ovarian Cancer
Interview with Jonathan Ledermann, BSc, MD, FRC...

State of Research in Ovarian Cancer

Characteristics and Symptoms of Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...

Characteristics and Symptoms of Ovarian Cancer

Ovarian Cancer Prognosis
Interview with Professor Ignace Vergote Chairm...

Ovarian Cancer Prognosis

Targeted Therapies in Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...

Targeted Therapies in Ovarian Cancer

Ovarian Cancer Animated Infographic

Ovarian Cancer Statistics Infographic

LUME-Ovar 1 December 2009
Boehringer Ingelheim initiates first Phase III ...

LUME-Ovar 1 December 2009

Breast Cancer Backgrounder

LUX-Breast 1 Infographic

LUX-Breast 3 Clinical Trial Infographic

LUX-Breast Clinical Trial Programme Infographic

Breast Cancer Animated Infographic

Lux Breast Cancer Trial August 2011
Boehringer Ingelheim Broadens its Breast Cancer...

Lux Breast Cancer Trial August 2011

Breast Cancer Statistics Infographic

Could new cancer targets change the outlook for personalised medicine?
Interview with Kathleen Pritchard, MD, FRCPC T...

Could new cancer targets change the outlook for personalised medicine?

LUX-Breast 1 Initiation September 2010
Boehringer Ingelheim Initiates Phase III Clinic...

LUX-Breast 1 Initiation September 2010

Head and Neck Cancer Backgrounder

LUX-Head & Neck 1 & 2 Trial Initiation
BI moves into Phase III for its Head and Neck C...

LUX-Head & Neck 1 & 2 Trial Initiation

LUX-Head & Neck 1 Trial Infographic

LUX-Head & Neck 2 Trial Infographic

Head and Neck Cancer
Interview with Ezra Cohen, MD Associate Profes...

Head and Neck Cancer

Head and Neck Cancer Treatments
Interview with Ezra Cohen, MD Associate Profes...

Head and Neck Cancer Treatments

Head and Neck Cancer Trials
Interview with Ezra Cohen, MD Associate Profes...

Head and Neck Cancer Trials

Head and Neck Cancer Infographic

BIBW 2992 cancer treatment data
BI's lead investigational oncology compound BIB...

BIBW 2992 cancer treatment data

Rare disease day Boehringer Ingelheim announces initiation of pivotal trial

Boehringer Ingelheim to initiate Phase III study in leukaemia

Volasertib* and Polo-like kinase (Plk) Inhibition Infographic

Volasertib* (compound code BI 6727)
Volasertib* (compound code BI 6727) is an inves...

Volasertib* (compound code BI 6727)

Clinical Trials E-Booklet Chapter 1
Introduction & Design of a Clinical Trial

Clinical Trials E-Booklet Chapter 1

Clinical Trials E-Booklet Chapter 2
Elements of a Clinical Trial

Clinical Trials E-Booklet Chapter 2

Clinical Trials E-Booklet Chapter 3
Clinical Trial Endpoints

Clinical Trials E-Booklet Chapter 3

Clinical Trials E-Booklet Chapter 4
Defining Progression

Clinical Trials E-Booklet Chapter 4

Clinical Trials E-Booklet Chapter 5
Clinical Trial Statistics

Clinical Trials E-Booklet Chapter 5

Clinical Trials E-Booklet Chapter 6
Summary, Checklist & Glossary

Clinical Trials E-Booklet Chapter 6

BI in Oncology Backgrounder

A-Z Cancer Glossary
The terminology around cancer research and canc...

A-Z Cancer Glossary

BI accesses field of oncology
BI accesses field of oncology with three compou...

BI accesses field of oncology

Welcome to NewsHome

The Changing Face of Cancer Infographic

Cancer statistics and incidence rates

A-Z Cancer Glossary

01.05.2011